Analysis Of Income And Expense [Abstract]

ABIONYX Pharma - Filing #2821124

Concept 2020-01-01 to
2020-12-31
2019-01-01 to
2019-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
0 EUR
0 EUR
Material income and expense [abstract]
Research and development expense
1 698 EUR
744,000 EUR
Finance income (cost)
1 082 EUR
4 412 EUR
Interest expense
0 EUR
0 EUR
Interest expense on borrowings
0 EUR
0 EUR
Selling, general and administrative expense [abstract]
Selling, general and administrative expense
1 270 EUR
1 781 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
0 EUR
0 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
1 891 EUR
1 849 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.